Newsroom

BOSTON, June 20, 2016 /PRNewswire/ — A next-generation antibiotic being developed by researchers at the New York-based pharmaceutical company TGV-inhalonix is significantly more effective than traditional drugs in fighting the rise in airway pathogens that cause life-threatening lung infections in cystic fibrosis patients, according to research presented today at ASM Microbe 2016.

BASEL, SWITZERLAND – 9 June, 2016 – A novel new drug being developed to treat antibiotic-resistant lung infections shows significant promise for treating the often life-threatening mixed bacterial and fungal lung infections contracted by cystic fibrosis patients, according to research presented today by TGV-inhalonix at the 39th European Cystic Fibrosis Conference.

NEW YORK, April 12, 2016 – TGV-Inhalonix, Inc., a New York-based pharmaceutical company, today announced that its new drug candidate for treating antibiotic-resistant bacterial lung infections in patients with cystic fibrosis has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA).

TGV-Inhalonix, Inc., a New York-based pharmaceutical company, recently announced that it has submitted an application for Orphan Drug Designation to the U.S. Food and Drug Administration (FDA) for its novel antibiotic Mul-1867, which shows promise in treating drug-resistant bacterial pulmonary infections in patients with cystic fibrosis.

12